CU20120118A7 - Compuestos bicíclicos y sus usos como inhibidores duales de c-src/jak - Google Patents
Compuestos bicíclicos y sus usos como inhibidores duales de c-src/jakInfo
- Publication number
- CU20120118A7 CU20120118A7 CU2012000118A CU20120118A CU20120118A7 CU 20120118 A7 CU20120118 A7 CU 20120118A7 CU 2012000118 A CU2012000118 A CU 2012000118A CU 20120118 A CU20120118 A CU 20120118A CU 20120118 A7 CU20120118 A7 CU 20120118A7
- Authority
- CU
- Cuba
- Prior art keywords
- src
- inhibitors
- jak
- present
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000009977 dual effect Effects 0.000 title abstract 2
- 102000015617 Janus Kinases Human genes 0.000 abstract 2
- 108010024121 Janus Kinases Proteins 0.000 abstract 2
- 102000038012 SFKs Human genes 0.000 abstract 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 abstract 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 102000001332 SRC Human genes 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000003831 deregulation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 108010087686 src-Family Kinases Proteins 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos bicíclicos aromáticos sustituidos que contienen anillos de pirimidina y piridina así como también sales aceptables para uso farmacéuticos de los mismos.Los compuestos de la presente invención son útiles como inhibidores de la tirosina quinasa, con preferencia inhibidores de la familia SRC de las quinasas( SFK), en particular como inhibidores múltiples de la SFK/JAK quinasas e incluso, con preferencia, como inhibidores duales de las c- SRC/JAK quinasas, inhibiendo así la activación de STAT3 y, por lo tanto, el crecimiento anormal de los tipos celulares particulares.Notablemente, los compuestos de la presente invención son útiles para el tratamiento o inhibición de ciertas enfermedades que son el resultado de la desregulación de STAT3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN415CH2010 | 2010-02-17 | ||
| PCT/IB2011/050669 WO2011101806A1 (en) | 2010-02-17 | 2011-02-17 | Bicyclic compounds and their uses as dual c-src / jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20120118A7 true CU20120118A7 (es) | 2012-10-15 |
Family
ID=43903941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2012000118A CU20120118A7 (es) | 2010-02-17 | 2012-08-15 | Compuestos bicíclicos y sus usos como inhibidores duales de c-src/jak |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8440679B2 (es) |
| EP (1) | EP2536722B1 (es) |
| JP (1) | JP2013519725A (es) |
| KR (1) | KR20120130294A (es) |
| CN (1) | CN102858770A (es) |
| AR (1) | AR089641A1 (es) |
| AU (1) | AU2011216895B2 (es) |
| BR (1) | BR112012020639A2 (es) |
| CA (1) | CA2789655A1 (es) |
| CU (1) | CU20120118A7 (es) |
| CY (1) | CY1115420T1 (es) |
| DK (1) | DK2536722T3 (es) |
| EA (1) | EA201290757A1 (es) |
| ES (1) | ES2470190T3 (es) |
| HR (1) | HRP20140437T1 (es) |
| IL (1) | IL221487A (es) |
| MX (1) | MX2012009482A (es) |
| NZ (1) | NZ602271A (es) |
| PH (1) | PH12012501654A1 (es) |
| PL (1) | PL2536722T3 (es) |
| PT (1) | PT2536722E (es) |
| RS (1) | RS53458B (es) |
| SA (1) | SA111320200B1 (es) |
| SG (1) | SG183329A1 (es) |
| SI (1) | SI2536722T1 (es) |
| SM (1) | SMT201400090B (es) |
| TW (1) | TW201130838A (es) |
| WO (1) | WO2011101806A1 (es) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| SI2432472T1 (sl) | 2009-05-22 | 2019-11-29 | Incyte Holdings Corp | 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| EP2825166A1 (en) * | 2012-03-12 | 2015-01-21 | Allergan, Inc. | Method of treating ophthalmic conditions with kinase inhibitors |
| EP2825537B1 (en) | 2012-03-12 | 2017-01-04 | Allergan, Inc. | Dihydropyridopyrimidine and dihydronaphthyridine derivatives as tyrosine kinase inhibitors of especially vegf and pdgf |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| PH12020551186B1 (en) | 2012-11-15 | 2024-03-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| US20160123982A1 (en) | 2013-02-04 | 2016-05-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2014196793A1 (en) * | 2013-06-05 | 2014-12-11 | C&C Research Laboratories | Heterocyclic derivatives and use thereof |
| SMT202000315T1 (it) | 2013-08-07 | 2020-07-08 | Incyte Corp | Forme di dosaggio a rilascio prolungato per un inibitore di jak1 |
| ES2933350T3 (es) | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| US9321766B1 (en) | 2014-10-06 | 2016-04-26 | Allergan, Inc. | Kinase inhibitors |
| US9296747B1 (en) | 2014-10-10 | 2016-03-29 | Allergan, Inc. | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| AU2016287568B2 (en) | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| RU2765181C2 (ru) | 2015-07-06 | 2022-01-26 | Тёрнинг Поинт Терапьютикс, Инк. | Полиморфная форма диарильного макроцикла |
| PT3733187T (pt) | 2015-07-21 | 2024-11-08 | Turning Point Therapeutics Inc | Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| CN107459519A (zh) * | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
| TWI808958B (zh) * | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US10392367B2 (en) | 2017-06-01 | 2019-08-27 | Quentis Therapeutics, Inc. | IRE1 small molecule inhibitors |
| JP7126084B2 (ja) | 2017-06-01 | 2022-08-26 | コーネル ユニバーシティー | Ｉｒｅ１小分子阻害薬 |
| WO2018222917A1 (en) * | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| CN111182903A (zh) | 2017-07-28 | 2020-05-19 | 特普医药公司 | 巨环化合物及其用途 |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| LT3728271T (lt) | 2017-12-19 | 2022-12-12 | Turning Point Therapeutics, Inc. | Makrocikliniai junginiai, skirti ligų gydymui |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| SG11202007164UA (en) | 2018-01-30 | 2020-08-28 | Incyte Corp | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| US12312416B2 (en) | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| CN109180657A (zh) * | 2018-10-31 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | Stat3抑制剂的制备方法 |
| CN109293641A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种芴类stat3抑制剂及其制备方法 |
| CN109485643A (zh) * | 2018-10-31 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种芴酮类stat3抑制剂及制备方法与应用 |
| CN109336868A (zh) * | 2018-10-31 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 吲哚类stat3抑制剂及其制备方法 |
| CN109369627A (zh) * | 2018-10-31 | 2019-02-22 | 南京先进生物材料与过程装备研究院有限公司 | 芴酮类stat3抑制剂晶型a及制备方法 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN115210252A (zh) | 2020-02-04 | 2022-10-18 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗二硝基苯酚的嵌合抗原受体 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4349472A (en) | 1979-04-27 | 1982-09-14 | Schering Corporation | (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| TR200003429T2 (tr) * | 1998-05-26 | 2001-07-23 | Warner-Lambert Company | Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler. |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| US6989385B2 (en) * | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2004279427B2 (en) * | 2003-10-08 | 2008-07-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| ES2329419T3 (es) * | 2006-01-31 | 2009-11-25 | F. Hoffmann-La Roche Ag | 7h-pirido(3,4-d)pirimidin-8-onas, su preparacion y uso como inhibidores de proteinas cinasas. |
| WO2008077062A2 (en) | 2006-12-19 | 2008-06-26 | Board Of Regents, The University Of Texas System | Suppression of stat3 reactivation after src kinase inhibition to treat cancer |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
| GB2467670B (en) * | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| EP2211620B1 (en) | 2007-10-25 | 2013-12-25 | Merck Sharp & Dohme Corp. | 3-PYRAZIN SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AS JANUS KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
-
2011
- 2011-02-16 SA SA111320200A patent/SA111320200B1/ar unknown
- 2011-02-17 JP JP2012553436A patent/JP2013519725A/ja not_active Ceased
- 2011-02-17 SI SI201130155T patent/SI2536722T1/sl unknown
- 2011-02-17 EA EA201290757A patent/EA201290757A1/ru unknown
- 2011-02-17 PT PT117094847T patent/PT2536722E/pt unknown
- 2011-02-17 WO PCT/IB2011/050669 patent/WO2011101806A1/en not_active Ceased
- 2011-02-17 DK DK11709484.7T patent/DK2536722T3/da active
- 2011-02-17 NZ NZ602271A patent/NZ602271A/xx not_active IP Right Cessation
- 2011-02-17 MX MX2012009482A patent/MX2012009482A/es active IP Right Grant
- 2011-02-17 KR KR1020127023889A patent/KR20120130294A/ko not_active Withdrawn
- 2011-02-17 EP EP11709484.7A patent/EP2536722B1/en not_active Not-in-force
- 2011-02-17 CA CA2789655A patent/CA2789655A1/en not_active Abandoned
- 2011-02-17 US US13/578,656 patent/US8440679B2/en not_active Expired - Fee Related
- 2011-02-17 AR ARP110100492A patent/AR089641A1/es unknown
- 2011-02-17 TW TW100105192A patent/TW201130838A/zh unknown
- 2011-02-17 PH PH1/2012/501654A patent/PH12012501654A1/en unknown
- 2011-02-17 AU AU2011216895A patent/AU2011216895B2/en not_active Expired - Fee Related
- 2011-02-17 SG SG2012060489A patent/SG183329A1/en unknown
- 2011-02-17 HR HRP20140437AT patent/HRP20140437T1/hr unknown
- 2011-02-17 BR BR112012020639A patent/BR112012020639A2/pt not_active IP Right Cessation
- 2011-02-17 RS RS20140277A patent/RS53458B/sr unknown
- 2011-02-17 CN CN2011800165418A patent/CN102858770A/zh active Pending
- 2011-02-17 ES ES11709484.7T patent/ES2470190T3/es active Active
- 2011-02-17 PL PL11709484T patent/PL2536722T3/pl unknown
-
2012
- 2012-08-15 CU CU2012000118A patent/CU20120118A7/es unknown
- 2012-08-15 IL IL221487A patent/IL221487A/en not_active IP Right Cessation
-
2013
- 2013-01-14 US US13/741,019 patent/US8962637B2/en not_active Expired - Fee Related
-
2014
- 2014-06-03 CY CY20141100393T patent/CY1115420T1/el unknown
- 2014-07-10 SM SM201400090T patent/SMT201400090B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SMT201400090B (it) | 2014-09-08 |
| MX2012009482A (es) | 2012-11-29 |
| AR089641A1 (es) | 2014-09-10 |
| DK2536722T3 (da) | 2014-05-26 |
| TW201130838A (en) | 2011-09-16 |
| IL221487A (en) | 2014-11-30 |
| WO2011101806A1 (en) | 2011-08-25 |
| KR20120130294A (ko) | 2012-11-30 |
| HK1178897A1 (en) | 2013-09-19 |
| HRP20140437T1 (hr) | 2014-08-29 |
| BR112012020639A2 (pt) | 2017-08-08 |
| CN102858770A (zh) | 2013-01-02 |
| JP2013519725A (ja) | 2013-05-30 |
| AU2011216895B2 (en) | 2015-11-05 |
| PH12012501654A1 (en) | 2018-02-07 |
| SA111320200B1 (ar) | 2014-02-16 |
| US8440679B2 (en) | 2013-05-14 |
| PL2536722T3 (pl) | 2014-11-28 |
| EA201290757A1 (ru) | 2013-04-30 |
| EP2536722A1 (en) | 2012-12-26 |
| US8962637B2 (en) | 2015-02-24 |
| PT2536722E (pt) | 2014-05-26 |
| US20130012518A1 (en) | 2013-01-10 |
| SI2536722T1 (sl) | 2014-10-30 |
| ES2470190T3 (es) | 2014-06-23 |
| RS53458B (sr) | 2014-12-31 |
| CY1115420T1 (el) | 2017-01-04 |
| SG183329A1 (en) | 2012-09-27 |
| CA2789655A1 (en) | 2011-08-25 |
| AU2011216895A1 (en) | 2012-09-27 |
| US20130143895A1 (en) | 2013-06-06 |
| EP2536722B1 (en) | 2014-04-16 |
| NZ602271A (en) | 2013-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20120118A7 (es) | Compuestos bicíclicos y sus usos como inhibidores duales de c-src/jak | |
| CU20130115A7 (es) | Compuestos y composiciones como inhibidores de trk | |
| CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
| DOP2014000188A (es) | Derivados macrocíclicos para el tratamiento de enfermedades | |
| UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
| CR11650A (es) | DERIVADOS BICICLICOS HETEROCICLICOS O ESPIROBICICLICOS HETEROCICLICOS ENLAZADOS, DE PIRAZOLO[1,5-a] PIRIMIDINAS, PROCEDIMIENTOS PARA SU PREPARACION Y USOS DE LOS MISMOS | |
| UY33440A (es) | ?compuestos pirimidinílicos para uso como inhibidores de atr?. | |
| MX339937B (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit. | |
| PH12014500351B1 (en) | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | |
| MX345830B (es) | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso. | |
| MX361815B (es) | Compuestos pirazolopirimidinicos como inhibidores de cinasas. | |
| CR20140223A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| UY35249A (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos | |
| MX2019003468A (es) | Derivados de tieno [3,2-d]pirimidina que tienen actividad inhibidora de las cinasas de proteina. | |
| UY31821A (es) | Compuestos y composiciones como inhibidores de quinasa | |
| CU20120059A7 (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
| BR112015019508A2 (pt) | formas sólidas de um inibidor de cdk4/6 seletivo | |
| MX2015012867A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| CO6620050A2 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| CR20140031A (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak | |
| PA8834001A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| CL2012000589A1 (es) | Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras. | |
| NI201200029A (es) | Compuestos y composiciones como inhibidores de cinasa de proteína | |
| ECSP14013215A (es) | Compuestos novedosos | |
| CO6680703A2 (es) | Derivados de 6,7-dihidro-3h-oxazolo(3,4-a)pirazin-5,8-diona |